Risperidone Dosing
For adults with schizophrenia, start risperidone at 2 mg daily and titrate to a target dose of 4-8 mg daily, with 4 mg being optimal for most patients. 1
Adult Dosing by Indication
Schizophrenia
- Initial dose: 2 mg daily (once or twice daily)
- Titration: Increase by 1-2 mg increments at intervals ≥24 hours as tolerated
- Target dose: 4-8 mg daily
- Effective range: 4-16 mg daily 1
Critical dosing insight: The 4 mg daily dose is optimal based on dose-response data. Doses above 6 mg twice daily show no additional efficacy and increase extrapyramidal symptoms 1, 2. Research specifically demonstrates that 4 mg daily represents the peak of the dose-response curve, with efficacy actually declining at 10 mg and above 2. The minimum effective dose for first-episode psychosis is 2 mg daily 3.
Bipolar Mania
- Initial dose: 2-3 mg daily
- Titration: Increase by 1 mg increments at intervals ≥24 hours
- Effective range: 1-6 mg daily 1
Special Populations - Adults
For elderly patients or those with severe renal/hepatic impairment:
- Initial dose: 0.5 mg twice daily
- Titration: May increase above 1.5 mg twice daily at intervals ≥1 week 1
Age-related pharmacokinetic consideration: Age significantly reduces risperidone clearance, and 20-26% of elderly patients have concentration-to-dose ratios above 14 ng/mL per mg/day, which correlates with increased extrapyramidal side effects 4, 5. For Alzheimer's patients, optimal dosing ranges from 0.25 mg/day (age 85, MMSE 5) to 1 mg/day (age 75, MMSE 15), with some requiring alternate-day dosing 5.
Pediatric Dosing by Indication
Schizophrenia (Adolescents 13-17 years)
- Initial dose: 0.5 mg once daily
- Titration: Increase by 0.5-1 mg increments at intervals ≥24 hours
- Target dose: 3 mg daily
- Effective range: 1-6 mg daily 1
Important caveat: While efficacy is demonstrated up to 6 mg daily, no additional benefit occurs above 3 mg daily, and higher doses increase adverse events 1, 6. The benefit-risk profile suggests 1-3 mg daily is optimal for adolescents 6.
Bipolar Mania (Children/Adolescents 10-17 years)
- Initial dose: 0.5 mg once daily
- Titration: Increase by 0.5-1 mg increments at intervals ≥24 hours
- Target dose: 1-2.5 mg daily
- Effective range: 1-6 mg daily 1
Autistic Disorder (Ages 5-16 years)
Weight-based dosing:
For patients <20 kg:
- Initial dose: 0.25 mg daily
- Day 4: May increase to 0.5 mg
- Further titration: 0.25 mg increments at intervals ≥2 weeks
- Target dose: 0.5 mg daily
- Effective range: 0.5-3 mg daily 1
For patients ≥20 kg:
- Initial dose: 0.5 mg daily
- Day 4: May increase to 1 mg
- Further titration: 0.5 mg increments at intervals ≥2 weeks
- Target dose: 1 mg daily
- Effective range: 0.5-3 mg daily 1
Critical evidence note: A controlled trial demonstrated that low doses (0.125-0.175 mg daily) were ineffective, while high doses (1.25-1.75 mg daily based on weight) showed significant efficacy 7. This establishes a clear threshold for therapeutic effect.
ICU Delirium (Infants ≤2 years)
- Initial dose: 0.1-0.25 mg daily (0.01-0.04 mg/kg)
- Frequency: Once or twice daily
- Mean dose: 0.17 mg (0.02 mg/kg) 8
This represents off-label use with limited but supportive safety data in 17 patients 8.
Key Dosing Principles
Titration Strategy
- Slower titration is appropriate for first-episode patients, elderly patients, and young patients 9
- The original 6 mg target was based on chronically impaired, hospitalized, drug-resistant patients and is not optimal for most patients 9
Maintenance and Reinitiation
- Patients responding acutely should maintain their effective dose beyond the acute episode 1
- After discontinuation, follow the initial titration schedule when reinitiating 1
- For first-episode psychosis with complete remission ≥2 years, taper over at least 6 months if discontinuation is chosen 3
Pharmacogenetic Considerations
CYP2D6 poor metabolizers: Reduce dose for aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone, and zuclopenthixol 10
CYP2D6 ultrarapid metabolizers: Consider dose increase or alternative drug for risperidone due to reduced efficacy 10
Critical Safety Warnings
Avoid Polypharmacy
Antipsychotic polypharmacy in first-episode psychosis increases relapse risk (RR=1.42), hospitalization (RR=1.24), extrapyramidal symptoms (RR=1.63), and all-cause mortality (RR=1.19) 3. Switch to clozapine rather than adding a second antipsychotic if two adequate trials fail.
Monitoring Requirements
- Somnolence: Dose-related; 41% at 16 mg/day vs 16% placebo 1. Consider twice-daily dosing if persistent 1
- Weight gain: Monitor closely in pediatrics; mean gain 2 kg in 3-8 weeks, 5.5 kg at 24 weeks 1
- Orthostatic hypotension: Risk minimized by limiting initial adult dose to 2 mg total 1
- Prolactin elevation: 49-87% of pediatric patients develop elevated levels 1